On December 31, 2025, Oncotelic Therapeutics, Inc. finalized subscription agreements with 22 accredited investors, issuing 44 units at $25,000 each, totaling $1.1 million. This funding includes convertible notes and warrants allowing investors to convert into shares of Oncotelic or its subsidiary, EdgePoint.